With its (upsized) $82.875 million dollar financing, Field Trip establishes itself as one of the industry leaders in the psychedelics space.
TSI EDITOR |
2021-02-26
TRIP gains access to the huge Brazilian market for its psilocybin truffles.
TSI EDITOR |
2021-02-25
Optimi Health has commenced public trading (symbol "OPTI"). The Company raised CAD$20.7 million for its IPO financing.
TSI EDITOR |
2021-02-25
PsyBio has commenced trading. Its focus is on drug development for the Mental Health Crisis.
TSI EDITOR |
2021-02-25
MINDCURE's new Director is a veteran of capital markets.
TSI EDITOR |
2021-02-22
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
TSI EDITOR |
2021-02-18
MINDCURE's first line of mushroom-based nootropics now available for sale.
TSI EDITOR |
2021-02-18
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
TSI EDITOR |
2021-02-17
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
TSI EDITOR |
2021-02-17
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
TSI EDITOR |
2021-02-16
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now